Description

Doxorubicin (doxorubicin) Concentrate for Infusions 2 mg/ml. 50 ml. (100 mg/50 ml.)

Ingredients:

Doxorubicin hydrochloride is the active ingredient in this concentrate for infusions.

Dosage:

The dosage of Doxorubicin concentrate for infusions is determined by the patient’s body surface area, medical condition, and response to treatment. It is administered intravenously by a healthcare professional.

Indications:

Doxorubicin concentrate for infusions is indicated for the treatment of various types of cancers including breast cancer, lung cancer, and ovarian cancer. It works by slowing or stopping the growth of cancer cells in the body.

Contraindications:

This medication is contraindicated in patients with severe heart problems, low blood cell counts, and those who are pregnant or breastfeeding. It should not be used in patients with a known hypersensitivity to doxorubicin.

Directions:

Administered under the supervision of a healthcare provider experienced in the use of cytotoxic chemotherapy. The infusion should be given slowly into a vein.

Scientific Evidence:

Doxorubicin is a widely studied chemotherapy drug with proven efficacy in various cancer types. Research published in the Journal of Clinical Oncology has shown that doxorubicin, when used in combination with other chemotherapy agents, significantly improves survival rates in patients with advanced cancers.

Additional Information:

It is essential to monitor cardiac function during doxorubicin therapy due to the potential for cardiotoxicity. Patients may experience side effects such as nausea, vomiting, and hair loss. Close monitoring and supportive care are crucial to manage these side effects effectively.

Pharmacological Effects: Doxorubicin exerts its antitumor effects by intercalating into DNA strands, inhibiting nucleic acid synthesis, and inducing DNA strand breaks, ultimately leading to cell death. Additionally, it generates free radicals that contribute to its cytotoxic effects.

Clinical Trials: Clinical trials have demonstrated the efficacy of doxorubicin in various cancer types, both as a single agent and in combination with other chemotherapy drugs. A study published in the New England Journal of Medicine highlighted the significant benefits of doxorubicin-based regimens in improving overall survival in patients with advanced sarcomas.